Rocket Pharmaceuticals (RCKT) Other Accumulated Expenses (2014 - 2026)

Rocket Pharmaceuticals (RCKT) has 13 years of Other Accumulated Expenses data on file, last reported at $4.2 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 43.4% year-over-year to $4.2 million; the trailing twelve-month figure through Mar 2026 stood at $4.2 million (up 43.4% YoY), and the FY2025 full-year result was $2.3 million, up 43.45% from the prior year.
• Other Accumulated Expenses climbed to $4.2 million in Q1 2026, from $2.3 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $4.2 million in Q1 2026 to a low of $645000.0 in Q2 2022.
• A 5-year average of $2.1 million and a median of $1.9 million in 2022 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses surged 371.58% in 2022 and tumbled 44.17% in 2025, its largest moves.
• Tracing RCKT's Other Accumulated Expenses over 5 years: stood at $2.3 million in 2022, then fell by 22.04% to $1.8 million in 2023, then retreated by 8.3% to $1.6 million in 2024, then surged by 43.45% to $2.3 million in 2025, then surged by 81.17% to $4.2 million in 2026.
• Business Quant data shows RCKT's Other Accumulated Expenses at $4.2 million in Q1 2026, $2.3 million in Q4 2025, and $2.7 million in Q3 2025.